Morgan Stanley’s Medicines Co MDCO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,057,383
Closed -$89.8M 6928
2019
Q4
$89.8M Buy
1,057,383
+756,359
+251% +$50.4M 0.02% 651
2019
Q3
$15.1M Sell
301,024
-31,209
-9% -$1.24M ﹤0.01% 1732
2019
Q2
$12.1M Buy
332,233
+282,029
+562% +$9.21M ﹤0.01% 1954
2019
Q1
$1.4M Sell
50,204
-66,016
-57% -$1.56M ﹤0.01% 3877
2018
Q4
$2.23M Sell
116,220
-60,074
-34% -$1.4M ﹤0.01% 3679
2018
Q3
$5.27M Sell
176,294
-3,820
-2% -$144K ﹤0.01% 3139
2018
Q2
$6.61M Sell
180,114
-22,039
-11% -$716K ﹤0.01% 2833
2018
Q1
$6.66M Buy
202,153
+19,997
+11% +$625K ﹤0.01% 2726
2017
Q4
$4.98M Buy
182,156
+58,231
+47% +$1.79M ﹤0.01% 3111
2017
Q3
$4.59M Buy
123,925
+9,551
+8% +$352K ﹤0.01% 3045
2017
Q2
$4.35M Sell
114,374
-19,260
-14% -$858K ﹤0.01% 3004
2017
Q1
$6.54M Sell
133,634
-85,877
-39% -$3.92M ﹤0.01% 2590
2016
Q4
$7.45M Buy
219,511
+156,711
+250% +$5.56M ﹤0.01% 2572
2016
Q3
$2.37M Buy
62,800
+31,362
+100% +$1.18M ﹤0.01% 3357
2016
Q2
$1.06M Buy
31,438
+10,001
+47% +$353K ﹤0.01% 3931
2016
Q1
$681K Sell
21,437
-56,475
-72% -$1.84M ﹤0.01% 4222
2015
Q4
$2.91M Sell
77,912
-281,983
-78% -$10.7M ﹤0.01% 3171
2015
Q3
$13.7M Buy
359,895
+109,002
+43% +$3.83M 0.01% 1689
2015
Q2
$7.18M Sell
250,893
-930,727
-79% -$25.9M ﹤0.01% 2450
2015
Q1
$33.1M Buy
1,181,620
+1,141,398
+2,838% +$32.1M 0.01% 1092
2014
Q4
$1.11M Sell
40,222
-122,572
-75% -$3.04M ﹤0.01% 4068
2014
Q3
$3.63M Buy
162,794
+92,686
+132% +$2.35M ﹤0.01% 2911
2014
Q2
$2.04M Sell
70,108
-72,852
-51% -$1.95M ﹤0.01% 3467
2014
Q1
$4.06M Sell
142,960
-65,852
-32% -$2.18M ﹤0.01% 2770
2013
Q4
$8.06M Buy
208,812
+88,685
+74% +$3.17M ﹤0.01% 2122
2013
Q3
$4.03M Sell
120,127
-70,769
-37% -$2.25M ﹤0.01% 2636
2013
Q2
$5.87M Buy
+190,896
New +$6.39M ﹤0.01% 2172

Other funds holding MDCO

Morgan Stanley's MDCO Position: Q1 2020 in Review

Morgan Stanley sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 1,057,383 shares — an estimated $89.8M sold.

Morgan Stanley first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $89.8M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.

  • Morgan Stanley reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
  • Morgan Stanley sold 1,057,383 Medicines Co shares in Q1 2020, an estimated $89.8M.
  • Morgan Stanley first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
  • Morgan Stanley's Medicines Co position peaked at $89.8M in Q4 2019.
  • 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.

Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.